President Donald Trump catalyzed a selloff in opioid-exposed stocks Thursday as he declared the national epidemic a public health emergency and renewed the government’s crackdown on fentanyl.
“I will be pushing the concept of non addictive painkillers very, very hard,” Trump said. “We’re going to be spending lots of money on coming up with a non-addictive solutions.”
His announced intent to increase regulations around prescription strength and frequency bears implications on the following drug pharmaceuticals and distributors:
- Insys Therapeutics Inc INSY
- Pain Therapeutics, Inc. PTIE
- BioDelivery Sciences International, Inc. BDSI
- Collegium Pharmaceuticals Inc COLL
- Zogenix, Inc. ZGNX
- Zynerba Pharmaceuticals Inc ZYNE
- Teva Pharmaceutical Industries Ltd (ADR) TEVA
- Egalet Corp EGLT
- Trevena Inc TRVN
- GW Pharmaceuticals PLC - ADR GWPH
- Pacira Pharmaceuticals Inc PCRX
- Cara Therapeutics Inc CARA
- Titan Pharmaceuticals, Inc. TTNP
- AmerisourceBergen Corp. ABC
- McKesson Corporation MCK
- Cardinal Health Inc CAH
the following pharmacies:
- CVS Health Corp CVS
- Walgreens Boots Alliance Inc WBA
- Rite Aid Corporation RAD
the pharmacy benefits manager Express Scripts Holding Company ESRX, and the substance abuse treatment center AAC Holdings Inc AAC.
Opiant Pharmaceuticals Inc OPNT, a developer of pharmacological treatments for substance use, addictive and eating disorders, was trading up 30 percent Thursday.
His strategy involves collaboration with the National Institutes of Health on marketing campaigns; use of Public Health Emergency funds; expansion of treatment opportunities; and cooperation with foreign governments, specifically China, to staunch the flow of drugs from international manufacturers.
“We have to work with other countries to stop these drugs where they originate,” he said. “We have no choice, we have to work together.”
Trump promoted participation in Saturday’s National Prescription Drug Takeback Day.
Related Links:
Every Generation Has Its Drug: How People Are Dealing With Opioids, The New (Old) Thing
Petmed Accused Of Marketing Animal Painkillers To Human Drug Users
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
